This Saturday, April 27th, 2019 several Sentry
BioPharma Services team members will be proudly participating in the 2019 Komen
Central Indiana Race for the Cure ®.
Over the years this event has raised more than $2 billion
dollars to help fund research, education, screening and treatment. ...
In its September issue, Pharmaceutical Commerce details the previous and expected contributions of biologic products to its forecast of cold-chain market growth predicting sales of cold-chain drugs and biologics will outpace overall industry growth through 2022.
It is reported that “as of 2018, global...
In a recent news release the FDA described research it has conducted regarding detection of protein carbonylation, an oxidative reaction that may occur in therapeutic protein drug products during manufacture, storage, use, and transport potentially causing structural alterations and threatening stability,...
Wholesale drug distributors are a link between manufacturers and health care professionals. Their role is to ensure prescription medications are delivered safely and efficiently to thousands of health care practitioners and pharmacies nationwide every day.
While the U.S. health care supply chain is one of the most secure and sophisticated in the world, there is a growing network of rogue wholesale drug distributors selling potentially unsafe drugs in the U.S. market.
Reduce the Chance of a Potentially Unsafe Drug Reaching Your Patients
In order to protect your patients from unsafe or ineffective drugs, the FDA urges health care professionals to verify that their supplier is licensed by the state. Drugs from rogue wholesale drug distributors may harm your patients and expose them to unknown risks or side effects. The FDA advises health care providers to know the source for prescription drugs.
Verify that Your Wholesale Drug Distributor is Licensed in Your State
Regulatory oversight shapes every dimension of controlled substances: licensing, registration, storage, security, use, inventory and controlled drug disposal. Finding a Drug Enforcement Administration (DEA) licensed partner to store, distribute and manage returns and destruction of Schedule III-V controlled substances while maintaining regulatory and quality standards required for a secure pharmaceutical supply chain can be a challenge. Sentry BioPharma Services provides seamless product management required to safeguard controlled substances which are brought into Sentry’s custody and care.
Features & Benefits of Sentry’s Controlled Substance Program
DEA Regulation Secure Storage – Inspected and approved by the Drug Enforcement Administration in 2014, Sentry’s state-of-the-art controlled substance capacity provides secure and reliable storage to support your pharmaceutical supply chain needs.
Controlled Substance Importation/Exportation – Sentry’s controlled substance importation and controlled substance exportation capabilities provide pharmaceutical organizations unique flexibility in the drug supply chain. This coupled with Sentry’s high quality standards affords pharmaceutical companies a competitive advantage throughout the drug development process.
Redundant Systems and Extensive Security Measures– Product safety, identity, strength, purity and quality (SISPQ) remain intact. Sentry features which support this agenda include:
Auxiliary power feeds and back-up systems
Continuous (24/7) security monitoring
Foreign Trade Zone (FTZ) status which allows controlled substances to be internationally shipped directly to Sentry where DEA, Customs & Border Patrol (CBP) and FDA clearances can be obtained within the security provided by Sentry’s GMP facility
Physical plant security
Redundant HVAC systems
Secure data and document programs
Pharmaceutical Labeling and Packaging – Sentry’s light pharmaceutical manufacturing capabilities help streamline clinical trial distribution and commercial drug distribution with one stop shop GMP labeling and GMP secondary packaging.
Drug Product Return and Drug Disposal Services – Sentry completes the controlled substance supply chain with a full-service approach to product guardianship. Our drug product return and drug destruction program ensures project integrity, reliable inventory tracking and public safety from development to launch.
For more information about how Sentry can provide controlled substance supply chain solutions for your project, contact Sentryvia email or by phone at 1-866-757-7400.
As part of the U.S. Drug Enforcement Administration’s (DEA’s) National Prescription Drug Take-Back Day Initiative (NTBI), people will be able to dispose of expired, unwanted or unused prescription drugs on Saturday, October 22, 2016 from 10:00 a.m. to 2:00 p.m. at numerous collection sites around the U.S.
The DEA collected a record amount of meds during the 11th annual National Prescription Drug Take-Back Day on April 30, 2016. According to the DEA’s May 6, 2016 press release, the DEA and over 4,200 of its state, local, and tribal law enforcement partners collected 893,498 pounds of unwanted medicines—about 447 tons—at almost 5,400 sites spread through all 50 states, beating its previous high of 390 tons in the spring of 2014 by 57 tons, or more than 114,000 pounds.
The top five states with the largest collections, in order, were:
Texas (almost 40 tons)
California (32 tons)
Wisconsin (31 tons)
Illinois (24 tons)
Massachusetts (24 tons)
“I am very proud of our state officials and residents,” said Ms. Jennifer Marcum, Sentry BioPharma Services’ chief executive officer. Ms. Marcum continued, “Indiana’s authorities collected 29,125 pounds (14.6 tons). That’s an enormous amount of unwanted prescription drugs and controlled substances to be safely removed from the pharmaceutical supply chain. The statistics best illustrate how much the people of Indiana care about this important matter; no question about it.”
Marcum continued, “During the event, people can anonymously bring unwanted prescription pharmaceuticals and over-the-counter (OTC) medications to a participating drop-off site for proper drug disposal by law enforcement authorities with no questions asked. The service is free and an ideal way to preserve the environment from pharmaceutical contamination. This is a terrific opportunity to safely dispose of accumulated prescription drugs and medications that may have expired or are simply unwanted.”
The FDA’s Ilisa Bernstein, Pharm.D., J.D., offers a few more helpful tips when discarding drugs:
Scratch out all identifying information on the prescription label to make it unreadable. This will help protect your identity and the privacy of your personal health information.
Do not give your medicine to friends. Doctors prescribe medicines based on your specific symptoms and medical history. Something that works for you could harm another person.
When in doubt about proper drug disposal, ask your pharmacist.
For more information about the DEA’s National Prescription Drug Take-Back Day Initiative, general public inquiries can be made by calling the DEA toll free at: 1-800-882-9539.
If you would like to learn more about Sentry’s pharmaceutical drug destruction services, please contact Sentryvia email or by phone at 1-866-757-7400.
The U.S. Foreign Trade Zone program was established by the Foreign Trade Zone Act of 1934 to “expedite and encourage foreign commerce” in the United States. Certain geographical areas, in or adjacent to Customs Ports of Entry, can obtain foreign-trade zone (FTZ) status and receive commercial merchandise under the same Customs standards as if it were outside the commerce of the United States. Any merchandise, including pharmaceutical products, admitted and held in a foreign trade zone can be exempt of any Customs duties, tariffs and other ad valorem taxes. No duty or back taxes are charged on “value-added,” or foreign-sourced parts or materials incorporated into a finished product using U.S. parts and labor until the product is officially imported into the U.S. Commerce. This tariff and tax relief lowers the costs of U.S.-based organizations engaged in international trade while creating and retaining employment and capital investment opportunities that result from those operations.
Benefits to the Biopharmaceutical Industry
Pharmaceutical and biopharmaceutical companies can take advantage of Sentry’s GMP temperature-sensitive pharmaceutical storage and light manufacturing facility, which resides in a foreign trade zone. Sentry’s zone allows drug product to reside within the product’s designated temperature range, (such as API, biologics, controlled substances, etc.), while awaiting clearance for importation by the CBP and approved for distribution by the Food & Drug Administration (FDA).
During its stay in the FTZ, the biopharmaceutical product can be further labeled and secondarily packaged while greatly mitigating the numerous logistic and economic challenges encountered throughout the drug importation and development process.
Unlimited Storage Terms
Term of pharmaceutical material storage in an FTZ is indefinite.
Eliminated U.S. Quota Restrictions
Product previously subject to quota limitations is now exempt from such restrictions.
Strengthened Foreign Pharmaceutical Supply Chain
Eliminate administrative and importation hold-ups at Customs and ports of entry by bringing product straight to our GMP pharmaceutical storage environments ensuring product integrity: safety, identity, strength, purity and quality (SISPQ) along the drug supply chain.
Uninterrupted Local Manufacture Prior to Importation
Product can be labelled, kitted and packaged and stored in the United States until need for importation into U.S. Commerce and Customs Clearance.
Expedited Release to Market
Product can be held in an FTZ until FDA approval, greatly reducing time and logistic hassle from manufacturer to end-user.
Duty Deferral or Duty Aversion
Import, admit and hold product without paying U.S. Customs duties.
Zero Inventory Taxes
All materials held in an FTZ are exempt from state, county and local ad valorem taxes.
Country of Origin Marking and Labeling
Country-of-origin labels are non-required on product admitted to an FTZ freeing companies from this expense.
Sentry BioPharma Services’ pharmaceutical supply chain management expertise and FTZ status across all storage environments ensures product integrity and project management flexibility.
For more information about how Sentry’s Foreign Trade Zone can help you optimize your medical and pharmaceutical import/export process, contact Sentryvia email or by phone at 1-866-757-7400.
Read more about the Greater Indianapolis Foreign Trade Zone: inzone.org
Sentry is going purple! On Friday, June 24, 2016 Sentry BioPharma Services invites employees to wear the color purple in recognition of Alzheimer’s and brain awareness month.
Alzheimer’s disease is the sixth leading cause of death in the United States; it kills more citizens annually than prostate and breast cancer combined. Worst of all, there presently is no cure for Alzheimer’s disease. Researchers possess great hope that there will be treatments that can stop or slow Alzheimer’s in the near future.
The National Institute on Aging (NIA), one of the 27 Institutes and Centers of the National Institutes of Health (NIH), leads a broad scientific effort to understand the nature of aging and to extend the healthy, active years of life. NIA is the primary Federal agency supporting and conducting Alzheimer’s disease research. For more information about Alzheimer’s disease, please watch the video below.
Several medications are approved by the U.S. Food and Drug Administration to treat symptoms of Alzheimer’s. Donepezil (Aricept®), rivastigmine (Exelon®), and galantamine (Razadyne®) are used to treat mild to moderate Alzheimer’s (donepezil can be used for severe Alzheimer’s as well). Memantine (Namenda®), is used to treat moderate to severe Alzheimer’s.
These drugs work by regulating neurotransmitters, the brain chemicals that transmit messages between neurons. They may help maintain thinking, memory, and communication skills and help with certain behavioral problems. However, these drugs don’t change the underlying disease process. They are effective for some but not all people and may help only for a limited amount of time.
For more information about how Sentry can implement a custom solution to meet your unique GMP storage and pharmaceutical cold chain challenges, contact Sentry via email or by phone at 1-866-757-7400, for a complimentary, no obligation phone call with one of Sentry’s problem-solving experts.
Sentry BioPharma Services attended the Controlled Substance Distributor Conference, hosted by the Drug Enforcement Administration (DEA), Office of Diversion Control, in Indianapolis, Indiana on May 10 – 11, 2016. The topics presented include prescription drug and chemical trends, ARCOS/record keeping, drug disposal and effective controls against drug diversion.
Jennifer Marcum, Sentry’s CEO, says, “Overall, the controlled substance distributors’ conference was informative with much emphasis being placed on the addiction epidemic, controlled substance trends and the emergence of illegal pain management clinics.” Ms. Marcum continued, “The DEA is very clear about compliance with 21 CFR 1306.04(a). The DEA wants to enable practitioners to issue prescriptions for legitimate medical purposes. The DEA expects all members of the pharmaceutical supply chain to manufacture according to GMPs, to tightly control inventory and to maintain accurate records.”
James A. Arnold, Acting Chief Liaison & Policy Section, addressed the opioid prescription problem, the public health epidemic and the impact on society.
Between 2000 and 2014, there has been a 137% increase in unintentional deaths due to a prescription overdose. 28,647 deaths involved an opioid in 2014. The number of deaths per year exceeds that of motor vehicle accidents. Opioid addiction and abuse is a very serious situation in the U.S. Heroin, an illegal highly addictive analgesic drug derived from morphine, usage and death rates skyrocketed in 2015. However, heroin is only part of the problem. More and more people are getting hooked on prescription painkillers, laced illicit drugs and lethal drug cocktails like the “Holy Trinity” consisting of hydrocodone, carisoprodol and alprazolam. Heroin mixed with fentanyl creates a deadly drug combo that is 100 times more potent than morphine. Just one-fourth of 1 mg of fentanyl is enough to be potentially fatal. Read more about the DEA’s 2015 Drugs of Abuse Report: https://www.dea.gov/pr/multimedia-library/publications/drug_of_abuse.pdf
PUBLIC HEALTH EPIDEMIC & TRENDS
An opioid and prescription drug abuse epidemic is sweeping the U.S., impacting all segments of society. Opioid-related hospitalizations and infections from contaminated needles have caused the total opioid-related healthcare costs to rise significantly. Read the DEA’s Drug Fact Sheet for the latest information on substances:https://www.dea.gov/druginfo/factsheets.shtml
IMPACT ON SOCIETY
The Federal Bureau of Investigation (FBI) and DEA have an effective enforcement program for arresting people and attacking the supply of the opiates. But to reduce the demand for the drugs, the FBI and DEA are collaboratively deploying outreach programs to educate the public about what lies in wait for somebody who experiments opioids.
To help increase awareness about this epidemic and to help educate young people on the dangers of addiction, the FBI and DEA have released the documentary Chasing the Dragon: The Life of an Opiate Addict, a compilation of heart-wrenching first-person accounts by addicts, and family members of addicts, about their experiences.
For more information about how Sentry can meet safety and regulatory demands for pharmaceutical packaging, GMP storage, drug distribution and controlled substance disposal, contact Sentry via email or by phone at 1-866-757-7400.